Earnings Feed
Start Free
Werewolf Therapeutics, Inc.·4

May 26, 6:18 PM ET

EVNIN LUKE 4

4 · Werewolf Therapeutics, Inc. · Filed May 26, 2026

Research Summary

AI-generated summary of this filing

Updated

Werewolf Therapeutics (HOWL) Director Luke Evnin Sells Shares

What Happened

  • Luke Evnin, a director (and an MPM/MPM‑related manager/member — see footnotes), sold a total of 191,762 Werewolf Therapeutics (HOWL) shares in three open‑market transactions between May 21–26, 2026, for aggregate proceeds of $86,561. All transactions are reported as sales (code S) and were effected pursuant to a Rule 10b5‑1 trading plan dated March 26, 2026. These were disposals (not purchases), so they are generally considered routine plan‑based sales rather than a direct bullish signal.

Key Details

  • Transaction dates, counts, prices and proceeds:
    • 2026‑05‑21: 36,387 shares at $0.42, proceeds $15,283 (weighted avg price range reported: $0.4126–$0.4426). (See filing footnotes F2, F3, F11.)
    • 2026‑05‑22: 87,425 shares at $0.45, proceeds $39,341 (weighted avg price range reported: $0.42–$0.4614). (See F6, F7, F5.)
    • 2026‑05‑26: 67,950 shares at $0.47, proceeds $31,937 (weighted avg price range reported: $0.4436–$0.4826). (See F9, F10, F8.)
  • Shares reported held after each transaction (by entity, per filing footnotes):
    • After 5/21 (F11): AM LLC 81,820; BV 2014 516,606; BV 2014(B) 34,455; AM BV2014 17,779; MPM OIF 113,025. (Total reported = 763,685)
    • After 5/22 (F5): AM LLC 98,467; BV 2014 621,710; BV 2014(B) 41,465; AM BV2014 21,397; MPM OIF 136,021. (Total reported = 919,060)
    • After 5/26 (F8): AM LLC 89,100; BV 2014 562,571; BV 2014(B) 37,521; AM BV2014 19,361; MPM OIF 123,082. (Total reported = 831,635)
  • Notable filing points:
    • Transactions were executed under a Rule 10b5‑1 plan dated March 26, 2026 (footnote F1).
    • Reported prices are weighted averages and each sale was made in multiple trades; the filing gives price ranges and offers to provide per‑trade breakdowns on request (F3, F7, F10).
    • The sales were made by MPM‑related entities (AM LLC, MPM BioVentures 2014, BV 2014(B), AM BV2014, MPM OIF). Per the filing (F4), Luke Evnin is a member/manager of those entities and disclaims beneficial ownership except to the extent of his pecuniary interest.
    • Filing date: May 26, 2026; Period of report begins May 21, 2026.

Context

  • These sales were executed under a pre‑arranged 10b5‑1 plan. Such plan sales are typically automated and pre‑set and do not necessarily reflect the insider’s current view of the company.
  • The trades were by investment vehicles managed or affiliated with Evnin (not necessarily direct personal sales). The filing disclaims direct beneficial ownership except for pecuniary interest, which is common for managers of investment vehicles.
  • For retail investors: purchases are generally more informative about insider conviction than routine, plan‑based sales. The filing notes the weighted‑average price ranges; the filer will provide per‑trade price details to the company, shareholders, or SEC staff upon request.

Insider Transaction Report

Form 4
Period: 2026-05-21
Werewolf Therapeutics, Inc.HOWL
EVNIN LUKE
Director
Transactions
  • Sale

    Common Stock

    [F1][F2][F3][F4][F5]
    2026-05-21$0.42/sh−36,387$15,283→ 919,060 total(indirect: See Footnotes)
  • Sale

    Common Stock

    [F1][F6][F7][F4][F8]
    2026-05-22$0.45/sh−87,425$39,341→ 831,635 total(indirect: See Footnotes)
  • Sale

    Common Stock

    [F1][F9][F10][F4][F11]
    2026-05-26$0.47/sh−67,950$31,937→ 763,685 total(indirect: See Footnotes)
Footnotes (11)
  • [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
  • [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4436 to $0.4826 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F11]The shares are held as follows: 81,820 by AM LLC, 516,606 by BV 2014, 34,455 by BV 2014(B), 17,779 by AM BV2014 and 113,025 by MPM OIF.
  • [F2]The shares were sold as follows: 3,899 by MPM Asset Management LLC ("AM LLC"), 24,614 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,642 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 847 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,385 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4126 to $0.4426 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  • [F5]The shares are held as follows: 98,467 by AM LLC, 621,710 by BV 2014, 41,465 by BV 2014(B), 21,397 by AM BV2014 and 136,021 by MPM OIF.
  • [F6]The shares were sold as follows: 9,367 by AM LLC, 59,139 by BV 2014, 3,944 by BV 2014(B), 2,036 by AM BV2014 and 12,939 by MPM OIF.
  • [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.42 to $0.4614 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F8]The shares are held as follows: 89,100 by AM LLC, 562,571 by BV 2014, 37,521 by BV 2014(B), 19,361 by AM BV2014 and 123,082 by MPM OIF.
  • [F9]The shares were sold as follows: 7,280 by AM LLC, 45,965 by BV 2014, 3,066 by BV 2014(B), 1,582 by AM BV2014 and 10,057 by MPM OIF.
Signature
/s/ Luke Evnin|2026-05-26

Documents

1 file
  • 4
    form4-05262026_100557.xmlPrimary